HRP20180009T1 - Agonisti receptora vazopresina-2 - Google Patents

Agonisti receptora vazopresina-2 Download PDF

Info

Publication number
HRP20180009T1
HRP20180009T1 HRP20180009TT HRP20180009T HRP20180009T1 HR P20180009 T1 HRP20180009 T1 HR P20180009T1 HR P20180009T T HRP20180009T T HR P20180009TT HR P20180009 T HRP20180009 T HR P20180009T HR P20180009 T1 HRP20180009 T1 HR P20180009T1
Authority
HR
Croatia
Prior art keywords
compound according
alkyl
compound
image
halogen
Prior art date
Application number
HRP20180009TT
Other languages
English (en)
Inventor
Kazimierz Wisniewski
Claudio Schteingart
Pierre Riviere
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of HRP20180009T1 publication Critical patent/HRP20180009T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/16Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)

Claims (16)

1. Spoj formule I: [image] ili njegova farmaceutski prihvatljiva sol, naznačen time da: R2 je H, C1-C4 alkil, halogen, -OH ili -O-C1-C4 alkil; R3 je H ili -CH2-OH ili -C(O)-NR5R6; R4 je H ili -C(=NH)-NH2; R5 i R6 su neovisno H, C1-C6 alkil, -CH2- ciklopropil, - ciklopropil ili arilalkil pod uvjetom da R5 i R6 nisu oba H; X i Y su neovisno -CH2- ili -S- pod uvjetom da X je -CH2-, Y nije -CH2-; Z je -CHR7- ili S i R7 je H ili C1-C4 alkil, halogen, -OH ili -O-C1-C4 alkil; R8 je H ili -CH3; i Ar je heteroaril ili fenil proizvoljno supstituiran s jednim C1-C4 alkilom, halogenom, -OH ili -O-C1-C4 alkilom.
2. Spoj prema patentnom zahtjevu 1 naznačen time da su R5 i R6 neovisno H, C1-C6 alkil ili arilalkil.
3. Spoj prema patentnom zahtjevu 1 naznačen time da samo X ili samo Y su -S-.
4. Spoj prema patentnom zahtjevu 1 naznačen time da X je -CH2-.
5. Spoj prema patentnom zahtjevu 1 naznačen time da su X i Y oba -S-.
6. Spoj prema bilo kojem od patentnih zahtjeva 1-5 naznačen time da Ar je tiofen.
7. Spoj prema bilo kojem od patentnih zahtjeva 1-6 naznačen time da R8 je -CH3.
8. Spoj prema bilo kojem od patentnih zahtjeva 1-7 naznačen time da R3 je -C(O)-NR5R6.
9. Spoj prema bilo kojem od patentnih zahtjeva 1-8 naznačen time da R5 je H i R6 je C1-C4 alkil.
10. Spoj prema bilo kojem od patentnih zahtjeva 1-8 naznačen time da oba od R5 i R6 su -CH2CH3.
11. Spoj prema bilo kojem od patentnih zahtjeva 1-10 naznačen time da R2 je halogen.
12. Spoj prema patentnom zahtjevu 11 naznačen time da R2 je -Cl.
13. Spoj prema patentnom zahtjevu 11 naznačen time da R2 je -F.
14. Spoj prema patentnom zahtjevu 1 naznačen time da je: spoj 5 [image] spoj 10 [image] spoj 13 [image] spoj 14 [image] spoj 21 [image] ili spoj 33 [image]
15. Farmaceutski pripravak koji sadrži spoj prema bilo kojem od patentnih zahtjeva 1-14 naznačen time da je za upotrebu za liječenje dijabetes insipidusa, primarne noćne enureze ili nokturije.
16. Upotreba spoja prema bilo kojem od patentnih zahtjeva 1-14 naznačena time da je za proizvodnju lijekova za liječenje dijabetes insipidusa, primarne noćne enureze ili nokturije.
HRP20180009TT 2013-07-26 2018-01-04 Agonisti receptora vazopresina-2 HRP20180009T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361859024P 2013-07-26 2013-07-26
US201461952073P 2014-03-12 2014-03-12
PCT/US2014/048317 WO2015013690A1 (en) 2013-07-26 2014-07-25 Vasopressin-2 receptor agonists
EP14755464.6A EP3024829B1 (en) 2013-07-26 2014-07-25 Vasopressin-2 receptor agonists

Publications (1)

Publication Number Publication Date
HRP20180009T1 true HRP20180009T1 (hr) 2018-02-09

Family

ID=51398870

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180009TT HRP20180009T1 (hr) 2013-07-26 2018-01-04 Agonisti receptora vazopresina-2

Country Status (28)

Country Link
US (2) US10131692B2 (hr)
EP (1) EP3024829B1 (hr)
JP (1) JP6387095B2 (hr)
KR (1) KR102198130B1 (hr)
CN (1) CN105492441B (hr)
AU (1) AU2014292860B2 (hr)
BR (1) BR112016000436B1 (hr)
CA (1) CA2919208A1 (hr)
DK (1) DK3024829T3 (hr)
EA (1) EA029392B1 (hr)
ES (1) ES2656039T3 (hr)
HK (1) HK1218647A1 (hr)
HR (1) HRP20180009T1 (hr)
HU (1) HUE035252T2 (hr)
IL (1) IL243730B (hr)
JO (1) JO3371B1 (hr)
LT (1) LT3024829T (hr)
MX (1) MX363355B (hr)
MY (1) MY183429A (hr)
PH (1) PH12016500044B1 (hr)
PL (1) PL3024829T3 (hr)
PT (1) PT3024829T (hr)
RS (1) RS56604B1 (hr)
SG (1) SG11201600031RA (hr)
SI (1) SI3024829T1 (hr)
TW (1) TWI640542B (hr)
WO (1) WO2015013690A1 (hr)
ZA (1) ZA201600145B (hr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0918652B1 (pt) 2008-09-17 2021-10-19 Chiasma, Inc. Composição farmacêutica compreendendo um meio hidrofóbico e uma forma sólida que compreende polipeptídeo e sal de ácido graxo de cadeia média, processo de produção da mesma e forma de dosagem oral
US10993984B2 (en) 2016-10-21 2021-05-04 Chiasma, Inc. Terlipressin compositions and their methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE399252B (sv) * 1976-05-24 1978-02-06 Ferring Ab Forfarande for framstellnign av antidiuretiskt verkande desamino-asparagin Ÿ4-d-argininŸ8-vasopressin
CA1246055A (en) * 1980-03-24 1988-12-06 Joseph H. Cort N-.omega.-substituted hormonogens of vasopressin and its synthetic analogs
DK153883A (da) 1982-04-20 1983-10-21 Ceskoslovenska Akademie Ved Vasopressin-analoge
SE501677C2 (sv) 1993-06-18 1995-04-10 Ferring Bv Biologiskt aktiva vasopressinanaloger, farmaceutiska preparat innehållande dem samt deras användning för framställning av läkemedel
US5500413A (en) * 1993-06-29 1996-03-19 Ferring Ab Process for manufacture of 1-deamino-8-D-arginine vasopressin
CZ292131B6 (cs) 2000-02-16 2003-08-13 Ústav organické chemie a biochemie AV ČR Synthetické analogy Desmopressinu chráněné v C-terminální sekvenci proti karboxyamidasovému štěpení

Also Published As

Publication number Publication date
US10745443B2 (en) 2020-08-18
MX363355B (es) 2019-03-21
NZ716342A (en) 2021-03-26
EP3024829B1 (en) 2017-11-08
SI3024829T1 (en) 2018-01-31
WO2015013690A1 (en) 2015-01-29
HK1218647A1 (zh) 2017-03-03
US20190194257A1 (en) 2019-06-27
BR112016000436A2 (hr) 2017-07-25
PH12016500044A1 (en) 2016-03-28
AU2014292860A1 (en) 2016-01-28
CN105492441B (zh) 2019-09-10
JP2016527255A (ja) 2016-09-08
TW201536815A (zh) 2015-10-01
CA2919208A1 (en) 2015-01-29
TWI640542B (zh) 2018-11-11
LT3024829T (lt) 2017-12-27
US10131692B2 (en) 2018-11-20
PT3024829T (pt) 2017-12-18
ZA201600145B (en) 2020-01-29
BR112016000436B1 (pt) 2022-07-05
SG11201600031RA (en) 2016-02-26
KR102198130B1 (ko) 2021-01-05
AU2014292860B2 (en) 2017-10-05
US20150307555A1 (en) 2015-10-29
IL243730A0 (en) 2016-04-21
MY183429A (en) 2021-02-18
EA201690219A1 (ru) 2016-11-30
JO3371B1 (ar) 2019-03-13
MX2016000525A (es) 2016-04-07
IL243730B (en) 2019-09-26
EP3024829A1 (en) 2016-06-01
HUE035252T2 (en) 2018-05-02
DK3024829T3 (en) 2017-12-04
PL3024829T3 (pl) 2018-04-30
JP6387095B2 (ja) 2018-09-05
PH12016500044B1 (en) 2016-03-28
ES2656039T3 (es) 2018-02-22
CN105492441A (zh) 2016-04-13
RS56604B1 (sr) 2018-02-28
KR20160034943A (ko) 2016-03-30
EA029392B1 (ru) 2018-03-30

Similar Documents

Publication Publication Date Title
HRP20211011T1 (hr) N-[4-fluor-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oksadiazol-3-il)metoksi]-1-piperidil]metil]tiazol-2-il]acetamid kao inhibitor oga
HRP20181052T1 (hr) Derivati 1,2,4-oksadiazola kao imunomodulatori
MX2014005635A (es) Derivados de 2 - (1,2,3 -triazol - 2 - il) benzamida y 3 - (1,2,3 - triazol - 2 - il) picolinamida.
HRP20170403T1 (hr) SUPSTITUIRANI BENZOAZEPINI KAO MODULATORI TOLL-u SLIČNIH RECEPTORA
RU2018135921A (ru) Стабилизированные составы ванкомицина
PH12015501339A1 (en) Indole carboxamide derivatives as p2x7 receptor antagonists
HRP20120830T1 (hr) Imidazolkarboksamidi
ES2626555T3 (es) Pyridone amides como moduladores de canales de sodio
MD20140072A2 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
HRP20150744T4 (hr) Modulatori farmakokinetičkih svojstava lijekova
MY161903A (en) Substituted piperidines as ccr3 antagonists
MX370354B (es) Ligando de receptor de neurotensina.
RS54708B1 (en) ARYLETINYL DERIVATIVES
MY169986A (en) Benzimidazole-proline derivatives
PH12016500806B1 (en) Urea derivative or pharmacologically acceptable salt thereof
HRP20141108T1 (hr) Antagonisti piperidinon karboksamid azaindan cgrp receptora
NZ709648A (en) Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-methyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl)benzamide and its mono hydrochloride salt
HRP20180009T1 (hr) Agonisti receptora vazopresina-2
PH12019502370A1 (en) Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
MX368859B (es) Formulaciones de dosis solida de un antagonista del receptor de orexina.
EA201101304A1 (ru) Новая кристаллическая форма vi агомелатина, ее получение и применение
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
HRP20211182T1 (hr) Dopamin d3 receptora selektivni antagonisti/djelomični agonisti; postupci izrade i njihova uporaba
PH12014502210A1 (en) Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one
RS53940B1 (en) HETEROARYL UNITS AS LIGANDS OF 5-HT4 RECEPTORS